Literature DB >> 21347173

A Controlled Vocabulary to Represent Sonographic Features of the Thyroid and its application in a Bayesian Network to Predict Thyroid Nodule Malignancy.

Yueyi I Liu1, Aya Kamaya, Terry S Desser, Daniel L Rubin.   

Abstract

It is challenging to distinguish benign from malignant thyroid nodules on high resolution ultrasound. Many ultrasound features have been studied individually as predictors for thyroid malignancy, none with a high degree of accuracy, and there is no consistent vocabulary used to describe the features. Our hypothesis is that a standard vocabulary will advance accuracy. We performed a systemic literature review and identified all the sonographic features that have been well studied in thyroid cancers. We built a controlled vocabulary for describing sonographic features and to enable us to unify data in the literature on the predictive power of each feature. We used this terminology to build a Bayesian network to predict thyroid malignancy. Our Bayesian network performed similar to or slightly better than experienced radiologists. Controlled terminology for describing thyroid radiology findings could be useful to characterize thyroid nodules and could enable decision support applications.

Entities:  

Year:  2009        PMID: 21347173      PMCID: PMC3041558     

Source DB:  PubMed          Journal:  Summit Transl Bioinform        ISSN: 2153-6430


Introduction

Thyroid cancer is the 7th most commonly diagnosed malignancy in females. The American Cancer Society estimates that 33,550 new cases of thyroid cancer will be diagnosed in 20071. Thyroid cancers most often present as thyroid nodules. It is crucial to distinguish malignant nodules from benign ones so that early intervention can be performed to reduce morbidity and mortality. Many sonographic features have been described and studied as potential predictors of thyroid malignancy. These include size, multiplicity, echogenicity, presence of microcalcifications, margin, contour, shape, architecture, and vascularity (see 2,3 for review). In the prior studies of individual features, no consistent terminology was adopted, and different studies examining the same feature use different names. Consequently, it is difficult to combine results across studies for meta-analysis or to build multi-feature models. Controlled vocabularies are lists of standard terms used to describe a domain. They have many benefits, including facilitating, communication, data mining, and data retrieval. An example is the Medical Subject Headings (MeSH), a controlled vocabulary created and maintained by the National Library of Medicine to index MedLine articles. Controlled terminology is appearing in radiology, such as breast imaging, where the BI-RADS controlled terminology is used to describe mammogram features. Recently, the radiology community built RadLex, a lexicon for uniform indexing and retrieval of radiology information resources4. RadLex has been translated into an ontology, which facilitates computational analysis and applications5. However, currently there is no controlled vocabulary to describe the sonographic features of the thyroid. We believe that more accurate diagnosis of thyroid nodules can be achieved by creating a model incorporating all the features seen in thyroid ultrasound imaging. Bayesian classifiers are multi-features models that have been used in many areas of medicine. For example, Burnside et al. built a Bayesian classifier to predict breast cancer risk based on mammography findings6. Kline et al. created a classifier to identify a low-risk subset of patients suspected of having a venous thromboembolism using clinical data that are readily available7. The goal of our work is to create a controlled vocabulary for sonographic features of the thyroid with the goal of providing a means of creating standard “imaging phenotype” descriptions of the images. We also hypothesize that such a controlled vocabulary can be used to drive decision support applications such as a Bayesian network for thyroid nodule classification.

Materials and Methods

We performed a systemic review and identified 16 articles2,8–22 that discussed either one or a number of sonographic features associated with either benign or malignant thyroid nodules. While reviewing this literature, we unified features that were the same but named differently, resulting in a controlled terminology of features for thyroid ultrasound imaging. For each feature, we identified how they were defined in each article. We also obtained from literature the sensitivity, specificity, and positive predictive values of these features for malignancy. When these data were not directly available from the literature, they were computed from raw data in the article, using the total number of nodules, the number of benign/malignant nodules with the feature, if such data were provided in the articles. W used the Netica development environment (http://www.norsys.com) to construct our Bayesian classifier and perform inference. We created a Bayesian network (BN) comprising a node for disease and nodes for the observed sonographic findings and patient demographics. We represented the pathology of thyroid nodules as a disease node with two states (benign vs. malignant). All sonographic features from our controlled terminology known to be predictors of malignancy were included in the BN. Given that age and gender also significantly influence the probability of a nodule being malignant, we included these demographic features in our model as well. The structure of our BN is shown in Figure 1. The pretest probabilities of thyroid malignancies by age and gender were derived from the SEER database (http://seer.cancer.gov/faststats/sites.php?site=Thyroid+Cancer).
Figure 1.

Our Bayesian classifier for thyroid nodules. All possible values for each node are listed.

To evaluate our classifier, we randomly selected 21 benign thyroid nodules and 20 malignant nodules from 37 patients who underwent ultrasound guided FNA in 2007 and early 2008. All final diagnoses were determined by pathology. The 20 malignant nodules included 18 papillary thyroid carcinomas, one lymphoma, and one poorly differentiated carcinoma. Follicular lesions were not included since FNA, the test used to establish the final diagnosis in our study, cannot distinguish benign follicular adenomas from malignant follicular carcinomas. We compared the performance of our classifier to that of two radiologists specializing in thyroid ultrasound, one with five years of experience (radiologist 1), the other with 20 years of experience (radiologist 2). They each rated each nodule on a scale of 1 to 5 (1-benign, 2-probably benign, 3-not sure, 4-probably malignant, 5-malignant). Receiver operating characteristic (ROC) curves were generated using the ROCKIT 1.1B software (http://www-radiology.uchicago.edu/krl/KRL_ROC/software_index6.htm). One radiologist was aware of the case mix (number of benign versus malignant nodules), and the other was not.

Results

We performed a comprehensive literature review and identified 16 articles that discussed sonographic features that may help identify malignant thyroid nodules. These features are listed in Table 1.
Table 1.

A systemic literature review revealed many sonographic features that may help distinguish malignant thyroid nodules from benign ones. Those in bold are terms selected for our controlled vocabulary.

CategoryFeatureReferences
CalcificationAll calcifications14,15
Punctuate calcification12
Coarse calcification10,12
Rim-only calcification12,17
Microcalcification2,9,10,16–20
MarginIrregular margin10,16–18
Blurred margin19
Smooth margin21
Microlobulated margin21
Macrolobulated margin21
Ill-defined margin12
ShapeTaller than wide2,13,16,17
Irregular shape10,17,18
Round/oval in shape10,17
EchogenicityHypoechoic2,9,12,13,17,19–21
Marked hyperechoic16,17,21
Mixed hypoechoic/isoechoic10
Heterogenous internal echogenicity18
ArchitectureSolid2,8,10–13,17–19,21
Almost solid (<25% cystic)8,12,21
Mixed (25–75% cystic)12
Cystic8,10–13,21
InvasionExtracapsular invasion present17–19
Nodal metastasis17,19
VascularityIntrinsic vascularity9–11,13,21
Perinodular vascularity9,10,21
Hypovascular10
A vascular9,11,13,21
HaloHalo present2,10,12,18
Halo present >=50%12
Halo present <50%12
Ring down artifactRing down artifact present22
The vocabulary used to describe lesions was highly varied. This was particularly true for the description of vascularity based on color Doppler patterns. Some articles divided vascularity into three broad categories: avascular, peripheral vascularity, or intrinsic vascularity9,21. Chan et al. listed intrinsic hypovascularity as another class10. Innuccilli et al studied only internal vascularity and ranked it for each nodule on a scale of 0–4 in order of increasing flow, with 0 corresponding to avascular, approximately 25% or less, 26% to 50%, 51% to 75%, and greater than 75% on color Doppler crosssectional imaging13. Frates et al also characterized the color flow of each nodule into 4 types, with 0 being avascular, 1 for minimal internal flow without a peripheral ring, 2 for a peripheral ring of flow (defined as >25% of the nodule’s circumference) but minimal or no internal flow, 3 for a peripheral ring of flow and a small to moderate amount of internal flow, and 4 for extensive internal flow with or without a peripheral ring11. To create a controlled vocabulary for the sonographic features of thyroid nodules, we selected only those descriptors that have been used in multiple studies (those highlighted in bold in table 1) (Fig. 1). We obtained the conditional probability table of the Bayesian network by two independent methods. In the first method, an aggregate sensitivity and specificity of each feature was calculated as the weighted average of these parameters from all the articles from which sensitivity and specificity are available, using our controlled terminology to unify features that were the same but named differently in each article. The weight used was the number of thyroid nodules studied in each article, so that the aggregate values were biased towards large studies. In the second method, we had an experienced radiologist supply conditional probabilities from her experience. These two sources of conditional probably agree remarkably (data not shown), except in the case of vascularity, which is most likely due to the varied definition of vascularity in the literature. As a result, we used the conditional probability table from the expert radiologist. Our model is evaluated using 41 thyroid nodules from 37 patients. ROC curves of our classifier and the radiologists’ predictions are shown in Figure 2. The area under the curve (Az) value of our model is 0.851 (95% confidence interval (CI): 0.745–0.939), which is similar to or slightly better than those of the radiologists (0.846 (CI: 0.678–0.943) for radiologist 1 and 0.719 (CI: 0.543–0.854) for radiologist 2). Using the classifier for decision support and choosing decision threshold of p=0.2 probability of malignancy (4 of 20 malignant nodules could be missed), only 5 of 21 (24%) benign nodules would undergo biopsy, implying PPV = 76%. At the p=1.0 decision threshold of malignancy (all malignant nodules would be biopsied), 16 out of 21 benign nodules (76%) would undergo biopsy, implying PPV = 56%.
Figure 2.

ROC curves for the Bayesian classifier and two radiologists.

Discussion

Ultrasound presents a rich set of features that are useful for diagnosing thyroid disease. Much of the literature has focused on evaluating one or a few features for the task of recognizing thyroid cancer. We wanted to use the full range of features to create a decision support model in evaluating thyroid nodules. However, creating this model was thwarted by the lack of controlled terminology for describing features. We performed a comprehensive literature review of sonographic features implicated in thyroid malignancy to create a controlled vocabulary using the common features. Controlled vocabularies have been advocated to standardize radiology reporting, to facilitate communication, data retrieval, and data analysis. However, our results demonstrate the benefit of controlled terminology for creating a decision support application—in our case, a BN to help diagnose malignant thyroid nodules. In our initial evaluation of the BN using 41 nodules from 37 patients, our classifier performed similarly or slightly better than expert radiologists. One of the radiologists (radiologist 2) evaluated the ultrasound images completely blinded. The other radiologist (radiologist 1), though unaware of the final diagnosis of each nodule, was familiar with the cases by enumerating the sonographic features of each nodule. Hence, radiologist 1 was likely biased by awareness of the prior probability of a nodule being malignant in our test cases. We plan to undertake a more thorough evaluation in which only cases which have never been seen by either radiologist will be used to reduce potential bias. One limitation of our controlled vocabulary is that it includes only features that are well studied. In the future, as the implication of other features become more evident, a more comprehensive vocabulary can be developed. Adopting controlled terminology for reporting imaging features could have benefit in other domains of imaging in terms of driving decision support, not only radiology but also potentially pathology.
  22 in total

1.  New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid.

Authors:  Eun-Kyung Kim; Cheong Soo Park; Woung Youn Chung; Ki Keun Oh; Dong Ik Kim; Jong Tae Lee; Hyung Sik Yoo
Journal:  AJR Am J Roentgenol       Date:  2002-03       Impact factor: 3.959

2.  Derivation and validation of a Bayesian network to predict pretest probability of venous thromboembolism.

Authors:  Jeffrey A Kline; Andrew J Novobilski; Christopher Kabrhel; Peter B Richman; D Mark Courtney
Journal:  Ann Emerg Med       Date:  2005-03       Impact factor: 5.721

3.  Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement.

Authors:  Mary C Frates; Carol B Benson; J William Charboneau; Edmund S Cibas; Orlo H Clark; Beverly G Coleman; John J Cronan; Peter M Doubilet; Douglas B Evans; John R Goellner; Ian D Hay; Barbara S Hertzberg; Charles M Intenzo; R Brooke Jeffrey; Jill E Langer; P Reed Larsen; Susan J Mandel; William D Middleton; Carl C Reading; Steven I Sherman; Franklin N Tessler
Journal:  Radiology       Date:  2005-12       Impact factor: 11.105

Review 4.  Ultrasound of thyroid nodules.

Authors:  Terry S Desser; Aya Kamaya
Journal:  Neuroimaging Clin N Am       Date:  2008-08       Impact factor: 2.264

5.  The predictive value of ultrasound findings in the management of thyroid nodules.

Authors:  C Cappelli; M Castellano; I Pirola; D Cumetti; B Agosti; E Gandossi; E Agabiti Rosei
Journal:  QJM       Date:  2006-12-17

6.  Ultrasonographic characteristics of thyroid nodules: prediction of malignancy.

Authors:  E Koike; S Noguchi; H Yamashita; T Murakami; A Ohshima; H Kawamoto; H Yamashita
Journal:  Arch Surg       Date:  2001-03

7.  Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features.

Authors:  Enrico Papini; Rinaldo Guglielmi; Antonio Bianchini; Anna Crescenzi; Silvia Taccogna; Francesco Nardi; Claudio Panunzi; Roberta Rinaldi; Vincenzo Toscano; Claudio M Pacella
Journal:  J Clin Endocrinol Metab       Date:  2002-05       Impact factor: 5.958

8.  Natural history of benign solid and cystic thyroid nodules.

Authors:  Erik K Alexander; Shelley Hurwitz; Jenny P Heering; Carol B Benson; Mary C Frates; Peter M Doubilet; Edmund S Cibas; P Reed Larsen; Ellen Marqusee
Journal:  Ann Intern Med       Date:  2003-02-18       Impact factor: 25.391

9.  Thyroid calcification and its association with thyroid carcinoma.

Authors:  Mark L C Khoo; Sylvia L Asa; Ian J Witterick; Jeremy L Freeman
Journal:  Head Neck       Date:  2002-07       Impact factor: 3.147

10.  Elastography: new developments in ultrasound for predicting malignancy in thyroid nodules.

Authors:  T Rago; F Santini; M Scutari; A Pinchera; P Vitti
Journal:  J Clin Endocrinol Metab       Date:  2007-05-29       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.